Ivosidenib and QTc interval prolongation
Result of checking the interaction of drug Ivosidenib and disease QTc interval prolongation for safety when used together.
When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.
Consumer:Patients treated with ivosidenib can develop QTc prolongation and ventricular arrhythmias. Concomitant use of ivosidenib with drugs known to prolong the QTc interval (e.g., antiarrhythmic medicines, fluoroquinolones, triazole antifungals, 5-HT3 receptor antagonists) and CYP3A4 inhibitors may increase the risk of QTc interval prolongation. Conduct monitoring of electrocardiograms (ECGs) and electrolytes. In patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval, more frequent monitoring may be necessary. Treatment should be interrupted or dose reduced if QTc increases to greater than 480 msec. Permanently discontinue ivosidenib in patients who develop QTc interval prolongation with signs or symptoms of life-threatening arrhythmia.
Ivosidenib - Wydłużenie odstępu QTc 
Ivosidenib - Prolongamento do intervalo QTc 
Ivosidenib - Pemanjangan selang QTc 
Ivosidenib - Perpanjangan interval QTc 
Ivosidenib - Prolungamento dell'intervallo QTc 
Ivosidenib - Allongement de l'intervalle QTc 
Ivosidenib - QTc-Intervallverlängerung 
Ivosidenib - Prolongación del intervalo QTc 
Ivosidenib - удлинение интервала QTc 
Ivosidenib - QTc aralığı uzaması 
Ivosidenib - إطالة فترة QTc 
Ivosidenib - QTc间隔延长